RECRUITING Not applicable ClinicalTrials.gov

Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families

Sponsor: Haukeland University Hospital • ClinicalTrials.gov ID: NCT05744310

Registry updated: 2026-09-21

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is two to three years. The patient physical and psychological sufferings in ALS are immense, and apart from Riluzole, there is no effective treatment. Care of advanced ALS have an estimated cost of 4-8 million NOK per year. Perhaps the most challenging topic of ALS care is the decision to extend ventilation support into the stages of disease that require treatment both during day and night. In these cases, treatment is clearly life-sustaining and although quality of life may be maintained, the burden of caregiving imposed upon family or health care workers is huge, regardless of tracheostomy (TIV) or non-invasive (NIV) modality. The present study is a longitudinal questionnaire study in Norway measuring overall quality of life, health-related quality of life, and disease-specific quality of life in ALS patients, partners and children before and after the introduction of life sustaining ventilation support. The investigators aim to increase the knowledge on how life-sustaining ventilation support with NIV or TIV affects the quality of life in ALS patients, life partners and children. The results from the study may provide crucial information for clinicians and patients on one of the most difficult ethical issues of ALS treatment. The investigators anticipate that this information will facilitate a shared decision making processes, weighing benefits and disadvantages in a wider perspective.

Interventions

Long term mechanical ventilation support (Device)
Patients that choose life prolonging treatment with long term mechanical ventilation support
No long term mechanical ventilation support (Device)
Patients that decline life prolonging treatment with long term mechanical ventilation support

Eligibility criteria

Inclusion criteria for patients: 1. A clinical diagnosis of probable ALS according to the revised El Escorial criteria 2. Progression of the illness leading the consulting physician to offer treatment with LTMV 3. Can communicate in Norwegian Inclusion criteria for partners of ALS patients: 1. Partner of a patient with ALS with progression of the illness leading the consulting physician to offer treatment with LTMV 2. Can communicate in Norwegian Inclusion criteria for children: 1. Children from 8 years and older having a parent who suffers from ALS with progression of the illness leading the consulting physician to offer treatment with LTMV 2. Can communicate in Norwegian Exclusion criteria for patients, partners and children of ALS patients: 1\. Potential participants with cognitive impairment or dementia.

Conditions

Amyotrophic Lateral Sclerosis Motor Neuron Disease Nervous System Diseases Spinal Cord Diseases Neurodegenerative Diseases TDP-43 Proteinopathies

Locations

Nordland Hospital Bodø — Bodø, Nordland, Norway
Sørlandet Hospital Trust — Kristiansand, Vest Agder, Norway
Haukeland University Hospital — Bergen, Norway
Akershus University Hospital — Lørenskog, Norway
Oslo University Hospital — Oslo, Norway
Østfold Hospital Kalnes — Sarpsborg, Norway
Stavanger University Hospital — Stavanger, Norway
Universitetssykehuset Nord-Norge — Tromsø, Norway
St. Olavs Hospital — Trondheim, Norway

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment